Patents Represented by Attorney Gerard Devlin
  • Patent number: 8071770
    Abstract: Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B, E1, E2, E3, E4, E5, G1, G2 and R6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: December 6, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Craig A. Stump, Cory R. Theberge, Michael R. Wood, C. Blair Zartman
  • Patent number: 8017642
    Abstract: In its many embodiments, the present invention provides a novel class of naphthene- and indane-type as inhibitors of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ?2C adrenergic receptors using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: September 13, 2011
    Assignee: Schering Corporation
    Inventors: Younong Yu, Pietro Mangiaracina, Kevin D. McCormick, Christopher W. Boyce
  • Patent number: 8003624
    Abstract: In its many embodiments, the present invention provides a novel class of indolines as inhibitors of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ?2C adrenergic receptors using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: August 23, 2011
    Assignees: Schering Corporation, Pharmacopeia, Inc.
    Inventors: Kevin D. McCormick, Christopher W. Boyce, Younong Yu
  • Patent number: 8003792
    Abstract: The present invention is directed to compounds of Formula I: (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: August 23, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Cory R. Theberge, Craig A. Stump, Xufang Zhang, Steven N. Gallicchio, C. Blair Zartman
  • Patent number: 7994325
    Abstract: Compounds of Formula I: (where variables R1, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: August 9, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Daniel V. Paone, Diem N. Nguyen, Anthony W. Shaw, Christopher S. Burgey, Thomas J. Tucker, Samuel L. Graham
  • Patent number: 7985748
    Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as ?2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the ?2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: July 26, 2011
    Assignees: Pharmacopeia Drug Discovery, Inc., Scheeing Corporation
    Inventors: Kevin D. McCormick, Christopher W. Boyce, Neng-Yang Shih, Robert G. Aslanian, Pietro Mangiaracina, Manuel de Lera Ruiz, Younong Yu, Purakkattle Biju, Chia-Yu Huang, Bo Liang, Ruiyan Liu, Rong-Qiang Liu, Lisa Guise-Zawacki
  • Patent number: 7964739
    Abstract: The invention relates to a novel process for the preparation of asenapine, i.e. trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, as well as to novel intermediate products for use in said process.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: June 21, 2011
    Assignee: N.V. Organon
    Inventor: Gerardus Johannes Kemperman
  • Patent number: 7960417
    Abstract: The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: June 14, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven P. Govek, Jean-Michel Vernier, Theodore Kamenecka, John H. Hutchinson, Richard Pracitto
  • Patent number: 7956202
    Abstract: Disclosed are novel amino acid derivatives of formula (I) and (II) processes for the preparation thereof, and their use in the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrole.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: June 7, 2011
    Inventors: Gerardus Johannes Kemperman, Jacobus Johannes Maria Van Der Linden, Michael R. Reeder
  • Patent number: 7893052
    Abstract: The present invention is directed to compounds of Formula I: and Formula II: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: February 22, 2011
    Inventors: Daniel Vincent Paone, Anthony W. Shaw
  • Patent number: 7872147
    Abstract: Disclosed are novel amino acid derivatives of formula (I) and (II) processes for the preparation thereof, and their use in the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrole.
    Type: Grant
    Filed: April 6, 2006
    Date of Patent: January 18, 2011
    Assignee: N. V. Organon
    Inventors: Gerardus Johannes Kemperman, Jacobus Johannes Maria Van Der Linden, Michael R. Reeder
  • Patent number: 7851464
    Abstract: Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, E1, E2, E3, E4, E5, G1, G2, J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: December 14, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Harold G. Selnick, Michael R. Wood, Cory R. Theberge, Craig A. Stump, Steven N. Gallicchio, C. Blair Zartman
  • Patent number: 7850973
    Abstract: The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of A? in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of A?, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to A?. In another aspect, the immunogenic fragment of A? is capable of elevating plasma A? levels. The immunogenic fragments comprise linear or multivalent peptides of A?. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: December 14, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Victor M. Garsky, Joseph G. Joyce, Paul M. Keller, Gene Kinney, Xiaoping Liang, John W. Shiver
  • Patent number: 7829699
    Abstract: An efficient synthesis for the preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1 -carboxamide, by coupling (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one and 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride with 1,1?-carbonyldiimidazole (“CDI”) as carbonyl source; and an efficient preparation of the potassium salt of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: November 9, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin Belyk, Nelo Rivera
  • Patent number: 7786306
    Abstract: The present invention provides a method of resolving piperdin-yl-alkylene-alcohols, in high yield at high enantiomeric purity, for example 2-piperidin-2-yl-ethanol.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: August 31, 2010
    Assignee: Schering Corporation
    Inventors: Frank Xing Chen, Maria M. Tamarez, Ji Xie
  • Patent number: 7776886
    Abstract: The present invention is directed to cyclopropyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neuro-transmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: August 17, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig W. Lindsley, David D. Wisnoski, Scott E. Wolkenberg
  • Patent number: 7772224
    Abstract: The present invention is directed to compounds of Formula I: and Formula II: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: August 10, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Daniel V. Paone, Anthony W. Shaw
  • Patent number: 7750010
    Abstract: The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, T, U, V, W, X, Y, Z, R4, R5a?, R5b, R5c, R6, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: July 6, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Steven N. Gallicchio, C. Blair Zartman, Cory R. Theberge, Xufang Zhang
  • Patent number: 7745427
    Abstract: The present invention is directed to compounds of Formula (I) and Formula (II) (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: June 29, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Daniel V. Paone, Diem N. Nguyen, Christopher S. Burgey, James Z. Deng
  • Patent number: 7732438
    Abstract: Compounds of Formula (I) and Formula (II) (where variables R1, R2, R4, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: June 8, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Daniel V. Paone, Anthony W. Shaw, Craig M. Potteiger